SLC5A2 and chronic kidney disease: These models will also preserve the tissue‐specific microenvironment that is critical for proper ion channel function.[66] Clinical trials and subgroup analyses may clarify the efficacy of combining TRPC6 blockade with therapies like SGLT2 inhibitors, potentially offering added benefit for CKD patients.[67] Moreover, we propose that future studies combine SH045 with SGLT2 inhibitors to evaluate potential synergistic effects.